Application of microRNA-15a measured in tumor tissues as a prognostic biomarker of the renal cell carcinoma
The aim of the study was to assess the potential for use microRNI-15a expression (miRNA), which was detected in tumor tissues as a prognostic biomarker of RCC.
The retrospective study included 64 patients with RCC after nephrectomy. For control 15 cases with healthy renal parenchymawere selected. Determination of miRNI-15a expression conducted after deparafinisation of blocks with tissuesamples with the following RNAisolation. MiRNAexpression was measuredusing reverse transcription and real-time polymerase chain reaction (PCR).
We achieved strong statistic evidence (p<0.01) of difference in miR-15a expression values in RCC tissues and in healthy renal parenchyma:1,52±2,62 relative units (RU) vs 4,53E-03±3,11E-03 RU accordingly. In patients with RCC median of miRNA-15a expression was significantly higher than in patients without renal pathology: 0,10±2,62 RUvs 4,84E-03±3,11E-03 RU. Higher levels of miRNA-15a expression was associated with larger tumor size (Pearson correlation coefficient r=0,724), higher level of nuclear atypia, presence of necrosis and involvementof the regional lymph nodes. Relationship between level of miRNI-15a expression values and histological subtype of RCC wasn’t detected. In patients with RCC and with the level of miRNA-15a expression Ј0,10 RU 3-year and 5-year cancer-specific survival (CSS) were 100% and 97,0% accordingly, the average duration of survival was 59,88±0,12 months (95% CI – 59,66–60,11); 3-year and 5-year CSS in patients with expression >0,10 RU were 83,9% and 54,8% accordingly, the average duration of survival was 49,74±2,16 months (95% CI – 59,66–60,11).
Higher levels of microRNA-15a expression was associated with symptoms of more aggressive biological behavior of the disease, 5-year CSS in patients with RCC and with high levels of miRNA-15a expression was lower than in patients with a level of expression <0,10 RU (p<0,001).MiRNI-15a can be used as a prognostic biomarker of RCC.
Full Text:PDF (Українська)
Федоренко З.П., Михайлович Ю.Й., Гулак Л.О. Рак в Україні, 2014–2015. / Бюл. нац. канцер-реєстру України №17. – Київ, 2015. – C. 56–57.
Pierorazio Phillip M., Michael H. et al. Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. // The Journal of Urology. – 2016 – V. 196, N 4. – P. 989–999.
Ljungberg B., Albiges L., Bensalah A. et al. EAU Guidelines on Renal Cell Carcinoma. European Association of Urology. – 2016. – Р. 17–20.
Keegan K.A. et al. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage // J. Urol. – 2012. – V. 188. – P. 391.
Leibovich B.C. et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma // J. Urol. – 2010. – V. 183. – P. 1309.
Wotschofsky Z., L. Gummlich, J. Liep, Carsten Stephan, ErginKilic, Klaus Jung, Jean-Noel Billaud, and Hellmuth-Alexander Meyer. Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p // PloS One. – 2016. – V. 11, N 2.
Nofech-Mozes Roy, Heba W. Z. Khella, Andreas Scorilas, Leza Youssef, Sergey N. Krylov, EviLianidou, Konstantinos G. Sidiropoulos, Manal Gabril, Andrew Evans, and George M. Yousef. MicroRNA-194 Is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma // Cancer Medicine. – 2016. – V. 5, N 4. – P. 656–664.
Samaan Sara, Heba W. Z. Khella, Andrew Girgis, Andreas Scorilas, EviLianidou, Manal Gabril, Sergey N. Krylov et al. miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma // The Journal of Molecular Diagnostics. – 2015. – N 2 . – P. 136–144.
Nakata Wataru, Motohide Uemura, Mototaka Sato, Kazutoshi Fujita, KentaroJingushi, Yuko Ueda, Kaori Kitae, KazutakeTsujikawa, and Norio Nonomura. Expression of miR-27a-3p Is an Independent Predictive Factor for Recurrence in Clear Cell Renal Cell Carcinoma // Oncotarget. – 2015. – N 25. – P. 21645–21654.
Terzuoli Erika, Sandra Donnini, Federica Finetti et al. Linking Microsomal Prostaglandin E Synthase-1/PGE-2 Pathway with miR-15a and -186 Expression: Novel Mechanism of VEGF Modulation in Prostate Cancer // Oncotarget. – 2016. – N 1. – P. 2–6.
Zhu Kang, Ying He, Cui Xia et al. MicroRNA-15a Inhibits Proliferation and Induces Apoptosis in CNE1 Nasopharyngeal Carcinoma Cells // Oncology Research. – 2016. – N 3(24). – P. 145–151.
Brandenstein Melanie, Jency J. Pandarakalam, Lukas Kroon et al. MicroRNA 15a, Inversely Correlated to PKCб, Is a Potential Marker to Differentiate between Benign and Malignant Renal Tumors in Biopsy and Urine Samples // The American Journal of Pathology. – 2012. – N. 5(180). – P. 1787–1797.